Obseva (NASDAQ:OBSV) was upgraded by investment analysts at TheStreet from a “d+” rating to a “c-” rating in a research report issued to clients and investors on Thursday.

A number of other equities analysts have also commented on OBSV. BMO Capital Markets raised their price objective on Obseva from $23.00 to $31.00 and gave the stock an “outperform” rating in a research note on Monday, June 18th. HC Wainwright set a $30.00 price objective on Obseva and gave the stock a “buy” rating in a research note on Monday, July 16th. Credit Suisse Group started coverage on Obseva in a research note on Thursday, July 19th. They set an “outperform” rating and a $24.00 price objective on the stock. Zacks Investment Research upgraded Obseva from a “sell” rating to a “buy” rating and set a $15.00 price objective on the stock in a research note on Wednesday, August 1st. Finally, Wedbush started coverage on Obseva in a research note on Monday, August 6th. They set an “outperform” rating and a $34.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Obseva presently has a consensus rating of “Buy” and an average target price of $28.00.

Obseva stock opened at $16.30 on Thursday. Obseva has a one year low of $8.79 and a one year high of $20.35. The firm has a market cap of $656.95 million, a price-to-earnings ratio of -7.24 and a beta of 1.49.

Obseva (NASDAQ:OBSV) last posted its quarterly earnings data on Wednesday, August 8th. The company reported ($0.49) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.05. On average, equities analysts forecast that Obseva will post -1.93 earnings per share for the current year.

Hedge funds have recently modified their holdings of the business. DRW Securities LLC boosted its holdings in shares of Obseva by 55.0% in the 2nd quarter. DRW Securities LLC now owns 33,812 shares of the company’s stock valued at $512,000 after purchasing an additional 12,000 shares in the last quarter. Vivo Capital LLC acquired a new stake in shares of Obseva in the 2nd quarter valued at $14,005,000. Laurion Capital Management LP acquired a new stake in shares of Obseva in the 2nd quarter valued at $2,271,000. Point72 Asset Management L.P. acquired a new stake in shares of Obseva in the 2nd quarter valued at $3,028,000. Finally, US Bancorp DE acquired a new stake in shares of Obseva in the 2nd quarter valued at $197,000. 68.26% of the stock is currently owned by hedge funds and other institutional investors.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Story: What is the 52-week high/low?

Analyst Recommendations for Obseva (NASDAQ:OBSV)

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.